Literature DB >> 1376988

bFGF enhances the development of the collateral circulation after acute arterial occlusion.

J O Chleboun1, R N Martins, C A Mitchell, T V Chirila.   

Abstract

An adequate collateral circulation is crucial to tissue survival subsequent to proximal major arterial occlusion. The precise mechanism of collateral blood vessel development and the biochemical mediators involved in this process are unknown. To evaluate the influence of a number of agents on the development of the collateral circulation, we developed a rat model of severe hind limb ischaemia. The recovery of blood flow after acute arterial occlusion was increased by exogenous basic fibroblast growth factor and heparin, and decreased by protamine. Erucamide (cis-13-docosenamide), an angiogenic lipid, had no effect on collateral blood flow. These results indicate that basic fibroblast growth factor and heparin are potential therapeutic agents in the treatment of peripheral vascular disease.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1376988     DOI: 10.1016/0006-291x(92)91654-9

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  3 in total

1.  Hepatocyte growth factor enhances vascular endothelial growth factor-induced angiogenesis in vitro and in vivo.

Authors:  X Xin; S Yang; G Ingle; C Zlot; L Rangell; J Kowalski; R Schwall; N Ferrara; M E Gerritsen
Journal:  Am J Pathol       Date:  2001-03       Impact factor: 4.307

2.  Basic fibroblast growth factor improves myocardial function in chronically ischemic porcine hearts.

Authors:  K Harada; W Grossman; M Friedman; E R Edelman; P V Prasad; C S Keighley; W J Manning; F W Sellke; M Simons
Journal:  J Clin Invest       Date:  1994-08       Impact factor: 14.808

Review 3.  Exercise training and peripheral arterial disease.

Authors:  Tara L Haas; Pamela G Lloyd; Hsiao-Tung Yang; Ronald L Terjung
Journal:  Compr Physiol       Date:  2012-10       Impact factor: 9.090

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.